EU/3/11/920

About

On 27 October 2011, orphan designation (EU/3/11/920) was granted by the European Commission to OctreoPharm Sciences GmbH, Germany, for gallium (68Ga)-pasireotide tetraxetan for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.

Key facts

Active substance
Gallium (68Ga)-pasireotide tetraxetan
Disease / condition
Diagnosis of gastro-entero-pancreatic neuroendocrine tumours
Date of decision
27/10/2011
Outcome
Positive
Orphan decision number
EU/3/11/920

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

OctreoPharm Sciences GmbH
Robert-Roessle-Str. 10
13125 Berlin
Germany
Tel. +49 30 948 93360
Fax +49 30 948 93364
E-mail: info@octreopharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating